Baldwin D, Rudge S
Ealing Mental Health Unit, Southall, Middlesex, UK.
Int Clin Psychopharmacol. 1995 Jan;9 Suppl 4:41-5. doi: 10.1097/00004850-199501004-00006.
Although many serotonin (5-hydroxytryptamine; 5-HT) receptors have been identified, our knowledge of many of the subtypes is limited. However, we do know that 5-HT1A agonists are involved in the treatment of certain anxiety disorders, that 5-HT1C and 5-HT2 receptor antagonists may be indicated for the treatment of generalized anxiety disorder, and that 5-HT1D receptor agonists are used in the treatment of migraine. Recent research has identified that various abnormalities in serotonergic function are involved in the pathogenesis of depression and anxiety, and has facilitated the development of new pharmacological agents with great therapeutic potential, for example the selective serotonin reuptake inhibitors (SSRIs). These agents appear to be effective in the treatment of many anxiety states and may have greater efficacy than other agents in the treatment of certain affective disorders. As the central serotonergic system continues to be "mapped", newer and more selective drugs are likely to be introduced, thereby possibly improving the overall successful management of depression and anxiety disorders.
虽然已识别出许多血清素（5-羟色胺；5-HT）受体，但我们对许多亚型的了解仍然有限。然而，我们确实知道5-HT1A激动剂参与某些焦虑症的治疗，5-HT1C和5-HT2受体拮抗剂可能适用于广泛性焦虑症的治疗，且5-HT1D受体激动剂用于偏头痛的治疗。最近的研究已确定，血清素能功能的各种异常与抑郁症和焦虑症的发病机制有关，并推动了具有巨大治疗潜力的新药研发，例如选择性5-羟色胺再摄取抑制剂（SSRI）。这些药物似乎对许多焦虑状态的治疗有效，且在某些情感障碍的治疗中可能比其他药物更有效。随着中枢血清素能系统不断被“绘制”，可能会推出更新、更具选择性的药物，从而有可能改善抑郁症和焦虑症的整体治疗效果。
